
AbbVie’s ABBV-295 shows promising weight loss and flexible dosing in Phase 1 obesity trial
AbbVie announced positive Phase 1 results for ABBV-295, a long-acting amylin analog for obesity treatment, showing meaningful weight loss of up to 9.8% over 12-13 weeks with weekly, biweekly, and monthly dosing options. The drug demonstrated a half-l...





